NEW HAVEN, Conn.,Oct. 15, 2024/PRNewswire/ --Trevi Therapeutics, Inc.(Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy HaduvioTM (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor and medical conferences in October and November.
3rd Chief Commercial Officer Summit
October 23-24, 2024,Philadelphia, PA
Oral Presentation:Commercial's Role in Clinical Trial Recruitment
Presentation:October 23, 1:30pm EDT
Trevi Representative:Farrell Simon, Chief Commercial Officer
Register here
BIO-Europe
November 4-6, 2024,Stockholm Sweden
Trevi Representative:Farrell Simon, Chief Commercial Officer
Register here
Stifel 2024 Healthcare Conference
November 18-19, 2024,New York, NY
Corporate Presentation:November 18, 11:30am EDT
Trevi Representatives:Jennifer Good, President and CEO, LisaDelfini, Chief Financial Officer
Register here to watch the live presentation
About Trevi Therapeutics, Inc.
TreviTherapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapyHaduvioTM (oralnalbuphineER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).Haduviois an extended-release (ER) dualĸ-opioidreceptoragonistandμ-opioidreceptor antagonist that works both centrally in the brain as well as peripherally in the lungs and has the potential for a synergisticantitussiveeffect to treat chronic cough.Parenteral nalbuphineis not scheduled by the U.S. Drug Enforcement Agency.
The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal benefit to patients. Chronic cough affects up to 10% of the adult population, and Haduvio's expansion into RCC has the potential to reach patients suffering from moderate to severe refractory chronic cough. There are also no approved therapies for RCC in the U.S.
Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
For more information, visitwww.TreviTherapeutics.comand follow Trevi onX(formerly Twitter) andLinkedIn.
Investor Contact
KatieBarrett
TreviTherapeutics, Inc.
203-304-2499
k.barrett@trevitherapeutics.com
Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com
SOURCE Trevi Therapeutics, Inc.
Katie McManus
(203) 903-9627
k.mcmanus@trevitherapeutics.com
Trevi Therapeutics
195 Church Street, 14th Floor
New Haven, CT 06510
map
